



# Treatment Choice of SAA with Omalizumab and OCS Sparing Benefit in Real World Practice

吳錦桐  
亞東醫院



# Conclusions

- Xolair® showed a marked OCS-sparing capacity and long-term improvement of FEV<sub>1</sub>.
- Airway remodeling reversed and improved epithelial damage in patients with severe asthma after Xolair® treatment.


# Conclusions

**Xolair**  
omalizumab

- ✓ Improved lung function
- ✓ Improved asthma control rate
- ✓ OCS sparing
- ✓ Reduced asthma exacerbation

**Patient with improved life quality**

Patient treated with omalizumab



# Outlines

- IgE plays an important role in allergic asthma
- Determination of biologics in severe asthma: Anti-IgE prioritized
- Xolair<sup>®</sup> benefits on OCS sparing and airway remodeling
- Conclusions